Yazar "Denizli, Bengu" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Analysis of early and last effects concomittant chemoradiotherapy of 24 patients with locally advanced cervical carcinoma (lacc)(Oxford Univ Press, 2004) Tokatli, Fusun; Uygun, Kazim; Ibis, Kamuran; Bayir, Gulden; Denizli, Bengu; Uzal, Cem[Abstract Not Available]Öğe Capecitabine-related intracranial hypotension syndrome mimicking dural metastasis in a breast cancer patient: Case report and review of the literature(Medknow Publications, 2010) Cosar-Alas, Rusen; Alas, Aykan; Ozen, Alaattin; Denizli, Bengu; Saynak, Mert; Uzunoglu, Sernaz; Aydogdu, NurettinSpontaneous intracranial hypotension (SICH) is an entity, which is secondary to iatrogenic manipulation and breaching of dura. Postural headache in patients should be suspected, cranial magnetic resonance imaging (MRI) is essential for precise diagnosis. Hallmark of MRI is regular shape of pachymeningeal gadolinium enhancement and subdural effusion. It may mimic central nervous system (CNS) metastasis. Prevention of such cases from receiving cranial radiotherapy by misinterpretation of the gadolinium enhancement as CNS metastasis is an important issue. Capecitabine is an antineoplastic agent, of which metabolites can cross blood-brain barrier in CNS via epithelial tissue. It may cause decrease in CSF production. SICH might be the clinical reflection of this decrease in CSF production. Review of the English literature revealed limited data because of the very little experience with oncologic patients suffering from intracranial hypotension. We report a case of spontaneous intracranial hypotension during capecitabine treatment. Patient was completely well following drug discontinuation and supportive treatment.Öğe Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: Is there a role for radiation therapy?(Bmc, 2011) Cosar, Rusen; Uzal, Cem; Tokatli, Fusun; Denizli, Bengu; Saynak, Mert; Turan, Nesrin; Uzunoglu, SernazBackground: We aimed to evaluate retrospectively the correlation of loco-regional relapse (LRR) rate, distant metastasis (DM) rate, disease free survival (DFS) and overall survival (OS) in a group of breast cancer (BC) patients who are at intermediate risk for LRR (T1-2 tumor and 1-3 positive axillary nodes) treated with or without postmastectomy radiotherapy (PMRT) following modified radical mastectomy (MRM). Methods: Ninety patients, with T1-T2 tumor, and 1-3 positive nodes who had undergone MRM received adjuvant systemic therapy with (n = 66) or without (n = 24) PMRT. Patient-related characteristics (age, menopausal status, pathological stage/tumor size, tumor location, histology, estrogen/progesterone receptor status, histological grade, nuclear grade, extracapsular extension, lymphatic, vascular and perineural invasion and ratio of involved nodes/dissected nodes) and treatment-related factors (PMRT, chemotherapy and hormonal therapy) were evaluated in terms of LRR and DM rate. The 5-year Kaplan-Meier DFS and OS rates were analysed. Results: Differences between RT and no-RT groups were statistically significant for all comparisons in favor of RT group except OS: LRR rate (3% vs 17%, p = 0.038), DM rate (12% vs 42%, p = 0.004), 5 year DFS (82.4% vs 52.4%, p = 0.034), 5 year OS (90,2% vs 61,9%, p = 0.087). In multivariate analysis DM and lymphatic invasion were independent poor prognostic factors for OS. Conclusion: PMRT for T1-2, N1-3 positive BC patients has to be reconsidered according to the prognostic factors and the decision has to be made individually with the consideration of long-term morbidity and with the patient approval.Öğe Protective effect of L-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats(Humana Press Inc, 2011) Uzunoglu, Sernaz; Karagol, Hakan; Ozpuyan, Fulya; Cosar, Rusen; Cicin, Irfan; Yurutcaloglu, Vuslat; Denizli, BenguWe aimed to compare the protective effect of L-carnitine (CAR) and amifostine (AMF) against cisplatin (CDDP)-induced nephrotoxicity through biochemical markers and histopathological evaluation. Fifty-seven Wistar albino male rats were randomly classified into six groups, which were AMF+CDDP (n = 11; 200 mg/kg AMF 30 min prior to 7 mg/kg CDDP), CAR? CDDP (n = 11; 300 mg/kg CAR 30 min prior to 7 mg/kg CDDP), CDDP (n = 11; 1 mL/kg isotonic saline 30 min prior to 7 mg/kg CDDP), AMF (n = 8; 200 mg/kg AMF alone), CAR (n = 8; 300 mg/kg CAR alone), and control (n = 8; 1 mL/kg isotonic saline alone). All drugs were given intra-peritoneally. Five days after medication, animals were killed, and samples of blood and kidney tissues were collected for biochemical and histopathological evaluation. The serum urea level was highest in AMF+CDDP group among CDDP-applied groups without statistical significance (median, range: 88, 56-21 mg/dL; P > 0.05). There was no statistical significance among CDDP-applied groups in terms of creatinine level (P > 0.05). In the AMF+CDDP group, the median glomerular, tubular, and tubulointerstitial inflammatory damage scores were significantly higher than the other CDDP-applied groups (P < 0.001). The difference between CAR? CDDP and CDDP groups was not statistically significant in terms of renal damage scores. AMF? CDDP group had significantly higher median total nephrotoxicity score than all the other groups (P < 0.001). To conclude, AMF or CAR has no protective effect on CDDP-induced nephrotoxicity. Furthermore, our findings suggest that application of AMF before CDDP may enhance CDDP-induced nephrotoxicity histopathologically.Öğe Small cell carcinoma of the prostate: case report and a review of the literature(Kare Publ, 2010) Denizli, Bengu; Yurut-Caloglu, Vuslat; Caloglu, Murat; Karagol, Hakan; Kaplan, Mustafa; Durmus-Altun, Gulay; Oz-Puyan, FundaSmall cell carcinoma of the prostate is a very rare and aggressive tumor, which accounts for 0.5-2% of all prostate carcinomas. Signs and symptoms include obstructive, neurologic and constitutional symptoms like bone pain, abdominal pain, hematochezia, and hematuria later followed by symptoms of paraneoplastic syndromes like ectopic ACTH secretion and inappropriate ADH secretion and myasthenic syndrome. Approximately, 75% of patients have advanced disease at diagnosis. The small number of patients in the literature prevents a consensus for an optimal treatment option. Because small cell carcinomas of the prostate and lung are identical, treatment options are similar. Chemotherapy is the mainstay of the treatment. Cisplatin/etoposide chemotherapy is frequently used. External radiotherapy is used with combination chemotherapy for local control in the limited disease, as well as for palliation in extensive disease. This report describes management of a 76-year-old patient with an advanced stage small cell carcinoma of the prostate in light of the reviewed literature.
